explore -WSS

explore

author：leisure time 2025-08-28 08:40:21 - browse：843

Novo Nordisk headquarters -- health coverage from STAT — Novo Nordisk's headquarters, outside Copenhagen, Denmark. LISELOTTE SABROE/Scanpix/AFP via Getty Images

Novo Nordisk is pausing ads for its obesity drug Wegovy as it struggles to keep up with surging demand, the latest hurdle in its rollout of the weight loss drug.

“To avoid stimulating further demand for this medicine, we’re pausing some key Wegovy promotional efforts,” the Danish drugmaker said in an emailed statement. “We are pausing all local television advertising and postponing planned national television advertising for Wegovy. We are also assessing our promotional efforts to healthcare professionals and adjusting accordingly.” The news was earlier reported by Endpoints.

Wegovy, which contains the active ingredient semaglutide, has become immensely popular for its effectiveness in helping people lose weight and is helping usher in what many see as a sea change in obesity treatment. Its sister drug for diabetes, Ozempic, has also been in demand for a similar effect on weight loss.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Continuity nursing helped my family in our darkest PICU moments
Next article： Congress must give Medicare recipients genetic counseling access

Wikipedia

focus

WSS

Emergency medicine has repudiated 'excited delirium.' Now what?

Patient advocates sound warning on FDA proposal on salt intake

FDA has safety concerns on CRISPR

Emergency medicine has repudiated 'excited delirium.' Now what?

Trump's false claims about Georgia's 2020 election long debunked

Meta's Zuckerberg and Chan on track to put $50 billion into science

entertainment

explore

entertainment

Guidelines to prevent youth baseball injuries need more muscle

Readout Newsletter: What happened with Sarepta's Duchenne data

Malaria cases in Florida and Texas: Here’s what you need to know

STAT Wunderkinds: Ruey Hu's digital tools for parsing research

The high cost of giving birth even with insurance

Testing for cancer recurrence creates a new limbo for patients

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Cassava reveals details — and problems — with Alzheimer's study

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Eye stem cell transplant could help restore vision in injured people

hotspot

Ukraine taking heavy casualties 10 weeks into its counteroffensive

Traditional Chinese medicine benefits explored in new JAMA study

Trump cancels press conference intended to dispute Georgia election interference charges

Trump cancels press conference intended to dispute Georgia election interference charges

ActiGraph execs on goal of drug approvals with digital endpoints

CDC recommends rationing of RSV shot due to shortages

Wikipedia

Wikipedia

focus

hotspot